Medtronic (MDT) Set to Announce Earnings on Tuesday
Medtronic (NYSE:MDT) is scheduled to be issuing its quarterly earnings data before the market opens on Tuesday, February 20th. Analysts expect the company to announce earnings of $1.17 per share for the quarter.
Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, November 21st. The medical technology company reported $1.07 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.08. The company had revenue of $7.05 billion for the quarter, compared to analyst estimates of $7.05 billion. Medtronic had a return on equity of 12.63% and a net margin of 16.93%. The business’s revenue was down 4.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.12 earnings per share. On average, analysts expect Medtronic to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.
Medtronic (MDT) opened at $80.24 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.40 and a quick ratio of 2.05. The company has a market capitalization of $107,580.00, a price-to-earnings ratio of 22.04, a price-to-earnings-growth ratio of 2.19 and a beta of 0.93. Medtronic has a one year low of $76.15 and a one year high of $89.72.
MDT has been the topic of a number of recent analyst reports. Needham & Company LLC reissued a “buy” rating and issued a $94.00 price objective on shares of Medtronic in a research note on Thursday, November 9th. SunTrust Banks set a $92.00 price objective on Medtronic and gave the stock a “buy” rating in a research note on Sunday, November 19th. Evercore ISI initiated coverage on Medtronic in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $92.50 price objective on the stock. Oppenheimer reissued a “buy” rating on shares of Medtronic in a research note on Thursday, December 21st. Finally, BMO Capital Markets boosted their price objective on Medtronic to $94.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 12th. Two equities research analysts have rated the stock with a sell rating, nine have given a hold rating and fifteen have issued a buy rating to the company. Medtronic has an average rating of “Buy” and a consensus price target of $90.10.
In other news, VP Richard Kuntz sold 78,526 shares of the business’s stock in a transaction on Tuesday, January 9th. The stock was sold at an average price of $86.21, for a total transaction of $6,769,726.46. Following the completion of the sale, the vice president now owns 149,761 shares in the company, valued at $12,910,895.81. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Hooman Hakami sold 26,158 shares of the business’s stock in a transaction on Friday, January 5th. The stock was sold at an average price of $85.00, for a total value of $2,223,430.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 136,684 shares of company stock valued at $11,582,596. 0.31% of the stock is currently owned by corporate insiders.
TRADEMARK VIOLATION NOTICE: “Medtronic (MDT) Set to Announce Earnings on Tuesday” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another website, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The legal version of this news story can be read at https://www.watchlistnews.com/medtronic-mdt-set-to-announce-earnings-on-tuesday/1862364.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.